Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topical product manufacturers receive one-third of FDA warning letters in FY 1996.

This article was originally published in The Tan Sheet

Executive Summary

TOPICAL PRODUCT MANUFACTURERS RECEIVED ONE-THIRD OF FY 1996 WARNING LETTERS from FDA for the year ended Sept. 30. Manufacturers of topical drugs were the recipients of 20 of the 59 warning letters issued by FDA during the fiscal year. Stability testing programs were a focal point of FDA concern; deficiencies in the stability area were addressed in more than two-thirds of the warning letters issued to topical manufacturing facilities.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS086738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel